Screener
CG Oncology CGON R&D
R&D at other companies
Other financials
Where this comes from
Reported directly by CG Oncology in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: CG Oncology’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 8:45 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336918
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Total revenues | 1,157 | — | 2,240 | 52 |
| Operating costs and expenses | ||||
| Cost of sales | 3,925 | — | 6,887 | — |
| Research and development | 54,657 | 31,331 | 98,387 | 58,799 |
| General and administrative | 28,976 | 17,410 | 49,756 | 32,198 |
| Total operating costs and expenses | 87,558 | 48,741 | 155,030 | 90,997 |
| Loss from operations | (86,401) | (48,741) | (152,790) | (90,945) |
| Other income (expense), net |
Item 1. Financial Statements.
FAQ
- What is CG Oncology's R&D?
- CG Oncology (CGON) reported R&D of $54.66M in Q2 2026.
- How has CG Oncology's R&D changed year-over-year?
- CG Oncology's R&D increased by 74.5% year-over-year, from $31.33M to $54.66M.
- What is the long-term trend for CG Oncology's R&D?
- Over 2 years (2023 to 2025), CG Oncology's R&D has grown at a 59.7% compound annual growth rate (CAGR), from $45.75M to $116.64M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about CG Oncology's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude